Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (511-520 of 744) with videos related to

Pageof 75
Sort By:
Journal for Immunotherapy of Cancer|January 27, 2026
Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanomaRobin Reschke, Petra Budde, Hans-Dieter Zucht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanomaAlexander M M Eggermont, Stefan Suciu, Alessandro Testori, et al.
JAAD International|June 17, 2024
Checkpoint inhibitor-induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression levelBarbara Meier-Schiesser, Christine Zecha, Sarah Zierold, et al.
The Lancet. Oncology|July 17, 2023
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 studyReinhard Dummer, Paola Queirolo, Pauline Gerard Duhard, et al.
Cancer Discovery|March 3, 2018
<i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance MechanismsJessica L F Teh, Phil F Cheng, Timothy J Purwin, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cellsMi He, Bhavesh Soni, Petra C Schwalie, et al.
European Journal of Cancer (Oxford, England : 1990)|January 6, 2020
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanomaPaolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Cancer Discovery|December 5, 2018
Correction: <i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance MechanismsJessica L F Teh, Phil F Cheng, Timothy J Purwin, et al.
The Lancet. Oncology|August 8, 2022
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 studyReinhard Dummer, Paola Queirolo, Ana Maria Abajo Guijarro, et al.
Plos One|March 4, 2014
TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trialBrigitte Dreno, Mirjana Urosevic-Maiwald, Youn Kim, et al.
Pageof 75

Showing results (511-520 of 744) with videos related to

Sort By:
Pageof 75
Journal for Immunotherapy of Cancer|January 27, 2026
Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanomaRobin Reschke, Petra Budde, Hans-Dieter Zucht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanomaAlexander M M Eggermont, Stefan Suciu, Alessandro Testori, et al.
JAAD International|June 17, 2024
Checkpoint inhibitor-induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression levelBarbara Meier-Schiesser, Christine Zecha, Sarah Zierold, et al.
The Lancet. Oncology|July 17, 2023
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 studyReinhard Dummer, Paola Queirolo, Pauline Gerard Duhard, et al.
Cancer Discovery|March 3, 2018
<i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance MechanismsJessica L F Teh, Phil F Cheng, Timothy J Purwin, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cellsMi He, Bhavesh Soni, Petra C Schwalie, et al.
European Journal of Cancer (Oxford, England : 1990)|January 6, 2020
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanomaPaolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Cancer Discovery|December 5, 2018
Correction: <i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance MechanismsJessica L F Teh, Phil F Cheng, Timothy J Purwin, et al.
The Lancet. Oncology|August 8, 2022
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 studyReinhard Dummer, Paola Queirolo, Ana Maria Abajo Guijarro, et al.
Plos One|March 4, 2014
TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trialBrigitte Dreno, Mirjana Urosevic-Maiwald, Youn Kim, et al.
Pageof 75